How to buy Akari Therapeutics stock

Akari Therapeutics, Plc is a biotechnology business based in the US. Akari Therapeutics shares (AKTX) are listed on the NASDAQ and all prices are listed in US Dollars. Akari Therapeutics employs 9 staff and has a market cap (total outstanding shares value) of 0.00.

Akari Therapeutics share price

Use our graph to track the performance of AKTX stocks over time.

Akari Therapeutics shares at a glance

• Key figures

Information last updated 2021-04-30.

52-week range	$1.42 - $4.21
50-day moving average	$2.60
200-day moving average	$2.31
Wall St. target price	$5.00
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-0.87

Buy Akari Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Akari Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Akari Therapeutics, Plc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Akari Therapeutics financials

Gross profit TTM	$0
Return on assets TTM	-101.26%
Return on equity TTM	-363.75%
Profit margin	0%
Book value	$0.24
Market capitalisation	$80.4 million

TTM: trailing 12 months

Shorting Akari Therapeutics shares

There are currently 71,910 Akari Therapeutics shares held short by investors – that's known as Akari Therapeutics's "short interest". This figure is 276.4% up from 19,103 last month.

There are a few different ways that this level of interest in shorting Akari Therapeutics shares can be evaluated.

Akari Therapeutics's "short interest ratio" (SIR)

Akari Therapeutics's "short interest ratio" (SIR) is the quantity of Akari Therapeutics shares currently shorted divided by the average quantity of Akari Therapeutics shares traded daily (recently around 299625). Akari Therapeutics's SIR currently stands at 0.24. In other words for every 100,000 Akari Therapeutics shares traded daily on the market, roughly 240 shares are currently held short.

However Akari Therapeutics's short interest can also be evaluated against the total number of Akari Therapeutics shares, or, against the total number of tradable Akari Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Akari Therapeutics's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Akari Therapeutics shares in existence, roughly 0 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Akari Therapeutics shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Akari Therapeutics.

Find out more about how you can short Akari Therapeutics stock.

Akari Therapeutics share dividends

We're not expecting Akari Therapeutics to pay a dividend over the next 12 months.

Have Akari Therapeutics's shares ever split?

Akari Therapeutics's shares were split on a 1:10 basis on 16 September 2015. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Akari Therapeutics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Akari Therapeutics shares which in turn could have impacted Akari Therapeutics's share price.

Akari Therapeutics share price volatility

Over the last 12 months, Akari Therapeutics's shares have ranged in value from as little as $1.42 up to $4.21. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Akari Therapeutics's is 1.2267. This would suggest that Akari Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Akari Therapeutics overview

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases. Its lead product candidate is Coversin, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, and atypical hemolytic uremic syndrome. Akari Therapeutics, Plc is based in London, the United Kingdom. .

Frequently asked questions

What percentage of Akari Therapeutics is owned by insiders or institutions?
Currently 28.619% of Akari Therapeutics shares are held by insiders and 21.174% by institutions. How many people work for Akari Therapeutics?
Latest data suggests 9 work at Akari Therapeutics. When does the fiscal year end for Akari Therapeutics?
Akari Therapeutics's fiscal year ends in December. Where is Akari Therapeutics based?
Akari Therapeutics's address is: 75/76 Wimpole Street, London, United Kingdom, W1G 9RT What is Akari Therapeutics's ISIN number?
Akari Therapeutics's international securities identification number is: US00972G1085 What is Akari Therapeutics's CUSIP number?
Akari Therapeutics's Committee on Uniform Securities Identification Procedures number is: 00972G108